文献速递心脑血管急症

利伐沙班联合或不联合阿司匹林治疗稳定性冠心病:一项国际、随机、双盲、安慰剂对照试验

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2017-11-10
一句话结论在稳定性冠心病患者中,利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次较阿司匹林单药降低主要复合终点(心肌梗死、卒中或心血管死亡)HR 0.74,但增加大出血HR 1.66,净获益支持联合治疗。

COMPASS试验在多中心、双盲、随机、安慰剂对照设计下,纳入24 824例稳定性冠心病患者,随机接受利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次、利伐沙班5 mg每日两次单药或阿司匹林100 mg每日一次单药。主要终点为心肌梗死、卒中或心血管死亡;联合治疗组主要终点发生率4% vs 阿司匹林组6%(HR 0.74,95%CI 0.65-0.86,p<0.0001),利伐沙班单药组5% vs 阿司匹林组6%(HR 0.89,95%CI 0.78-1.02,p=0.094)无显著改善。联合治疗组大出血发生率3% vs 阿司匹林组2%(HR 1.66,95%CI 1.37-2.03,p<0.0001),利伐沙班单药组3% vs 阿司匹林组2%(HR 1.51,95%CI 1.23-1.84,p<0.0001),最常见部位为胃肠道。联合治疗组全因死亡3% vs 阿司匹林组4%(HR 0.77,95%CI 0.65-0.90,p=0.0012),降幅23%。作者认为,利伐沙班联合阿司匹林可降低主要血管事件但增加大出血,颅内出血或其他关键器官出血无显著增加,净获益支持联合治疗。

要点

  • 稳定性冠心病患者中,利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次较阿司匹林单药降低主要终点(心肌梗死、卒中或心血管死亡):4% vs 6%,HR 0.74(95%CI 0.65-0.86),p<0.0001。
  • 联合治疗组大出血发生率3% vs 阿司匹林单药2%,HR 1.66(95%CI 1.37-2.03),p<0.0001;最常见出血部位为胃肠道(联合组2%,利伐沙班单药组1%,阿司匹林组1%)。
  • 利伐沙班5 mg每日两次单药较阿司匹林单药未显著改善主要终点:5% vs 6%,HR 0.89(95%CI 0.78-1.02),p=0.094。
  • 联合治疗组全因死亡3% vs 阿司匹林组4%,HR 0.77(95%CI 0.65-0.90),p=0.0012,死亡风险降低23%。
  • 作者结论:利伐沙班联合阿司匹林降低主要血管事件但增加大出血,颅内出血或其他关键器官出血无显著增加,联合治疗具有显著净获益。

适用人群与场景

  • 稳定性冠心病患者,须满足以下至少一项:过去20年内发生过心肌梗死、多支冠状动脉病变、稳定性或不安性心绞痛病史、既往多支经皮冠状动脉介入治疗、既往多支冠状动脉旁路移植术。
  • 试验在33个国家602家医院、诊所或社区中心招募,本报告纳入其中558个中心的稳定性冠心病患者。
  • 门诊患者,经过30天导入期后随机分组。

处置流程与药物剂量

  • 随机分组为1:1:1:利伐沙班2.5 mg口服每日两次联合阿司匹林100 mg口服每日一次;或利伐沙班5 mg口服每日两次单药;或阿司匹林100 mg口服每日一次单药。
  • 主要终点为心肌梗死、卒中或心血管死亡。

研究设计与关键结果

  • COMPASS试验为多中心、双盲、随机、安慰剂对照的门诊试验,2013年3月12日至2016年5月10日共纳入27 395例患者,其中24 824例稳定性冠心病患者来自558个中心。
  • 联合治疗组主要终点事件347/8313(4%)vs 阿司匹林单药组460/8261(6%),HR 0.74(95%CI 0.65-0.86),p<0.0001。
  • 利伐沙班单药组主要终点事件411/8250(5%)vs 阿司匹林单药组460/8261(6%),HR 0.89(95%CI 0.78-1.02),p=0.094,未达统计学显著。
  • 联合治疗组大出血263/8313(3%)vs 阿司匹林单药组158/8261(2%),HR 1.66(95%CI 1.37-2.03),p<0.0001;利伐沙班单药组大出血236/8250(3%)vs 阿司匹林单药组158/8261(2%),HR 1.51(95%CI 1.23-1.84),p<0.0001。
  • 大出血最常见部位为胃肠道:联合治疗组130例(2%),利伐沙班单药组84例(1%),阿司匹林单药组61例(1%)。
  • 联合治疗组全因死亡262/8313(3%)vs 阿司匹林单药组339/8261(4%),HR 0.77(95%CI 0.65-0.90),p=0.0012,死亡风险降低23%。
  • 颅内出血或其他关键器官出血无显著增加。

证据类型、等级与局限

  • 证据类型:国际、多中心、随机、双盲、安慰剂对照试验(COMPASS试验)。
  • 作者结论:在稳定性冠心病患者中,阿司匹林基础上加用利伐沙班降低主要血管事件但增加大出血,颅内出血或其他关键器官出血无显著增加,联合治疗具有显著净获益,死亡风险降低23%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于符合条件的稳定性冠心病门诊患者,作者认为阿司匹林基础上加用利伐沙班2.5 mg每日两次可降低主要血管事件和死亡,但需权衡大出血风险增加。
  • 利伐沙班5 mg每日两次单药较阿司匹林单药未显著改善主要终点,作者未推荐该单药方案替代阿司匹林。
  • 联合治疗组胃肠道大出血发生率高于阿司匹林单药组(2% vs 1%),临床决策时需考虑出血风险。

指南或共识出处

  • COMPASS试验(ClinicalTrials.gov注册号NCT01776424),发表于Lancet,由Bayer AG资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease.

METHODS: In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospitals, clinics, or community centres in 33 countries. This paper reports on patients with coronary artery disease. Eligible patients with coronary artery disease had to have had a myocardial infarction in the past 20 years, multi-vessel coronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, patients were randomly assigned (1:1:1) to receive rivaroxaban (2·5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day). Randomisation was computer generated. Each treatment group was double dummy, and the patients, investigators, and central study staff were masked to treatment allocation. The primary outcome of the COMPASS trial was the occurrence of myocardial infarction, stroke, or cardiovascular death. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.

FINDINGS: Between March 12, 2013, and May 10, 2016, 27 395 patients were enrolled to the COMPASS trial, of whom 24 824 patients had stable coronary artery disease from 558 centres. The combination of rivaroxaban plus aspirin reduced the primary outcome more than aspirin alone (347 [4%] of 8313 vs 460 [6%] of 8261; hazard ratio [HR] 0·74, 95% CI 0·65-0·86, p<0·0001). By comparison, treatment with rivaroxaban alone did not significantly improve the primary outcome when compared with treatment with aspirin alone (411 [5%] of 8250 vs 460 [6%] of 8261; HR 0·89, 95% CI 0·78-1·02, p=0·094). Combined rivaroxaban plus aspirin treatment resulted in more major bleeds than treatment with aspirin alone (263 [3%] of 8313 vs 158 [2%] of 8261; HR 1·66, 95% CI 1·37-2·03, p<0·0001), and similarly, more bleeds were seen in the rivaroxaban alone group than in the aspirin alone group (236 [3%] of 8250 vs 158 [2%] of 8261; HR 1·51, 95% CI 1·23-1·84, p<0·0001). The most common site of major bleeding was gastrointestinal, occurring in 130 [2%] patients who received combined rivaroxaban plus aspirin, in 84 [1%] patients who received rivaroxaban alone, and in 61 [1%] patients who received aspirin alone. Rivaroxaban plus aspirin reduced mortality when compared with aspirin alone (262 [3%] of 8313 vs 339 [4%] of 8261; HR 0·77, 95% CI 0·65-0·90, p=0·0012).

INTERPRETATION: In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding. There was no significant increase in intracranial bleeding or other critical organ bleeding. There was also a significant net benefit in favour of rivaroxaban plus aspirin and deaths were reduced by 23%. Thus, addition of rivaroxaban to aspirin has the potential to substantially reduce morbidity and mortality from coronary artery disease worldwide.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID: 29132879. doi:10.1016/S0140-6736(17)32458-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。